辅酶Q10联合多巴丝肼治疗帕金森病60例临床评价

Clinical Evaluation of Coenzyme Q10 Combined with Levodopa and Benserazide Hydrochloride Tablets for Treating Parkinson's Disease in 60 Cases

目的探讨辅酶Q10联合多巴丝肼治疗帕金森病的临床疗效、安全性及对患者生活质量的影响。方法选取医院2015年1月至2016年12月收治的帕金森病患者120例,随机分为研究组和对照组,各60例。对照组患者给予传统的基础药物如盐酸美金刚、多奈哌齐治疗,研究组患者在此基础上给予辅酶Q10+多巴丝肼治疗,两组患者均治疗6个月。结果研究组总有效率为73.33%,显著高于对照组的48.33%(P<0.05);治疗后,研究组患者蒙特利尔认知评估量表(MOCA)评分及BI指数评分均高于对照组(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论辅酶Q10辅助治疗帕金森病能明显改善患者认知障碍、情绪障碍,疗效佳,且不良反应少,能极大地提高患者的生活质量,值得临床推广。

Objective To investigate the clinical efficacy and safety of coenzyme Q10combined with Levodopa and Benserazide Hydrochloride Tablets in the treatment of Parkinson's disease and its effect on the quality of life of patients.Methods Totally120patients with Parkinson’s disease admitted to our hospital from January2015to December2016were randomly divided into the study group and the control group,60cases in each group.The control group was given traditional basic drugs such as memantine and donepezil,on this basis,the study group was given coenzyme Q10combined with Levodopa and Benserazide Hydrochloride Tablets.The two groups were treated for6months.Results The total effective rate of the study group was73.33%,which was significantly higher than48.33%of the control group(P<0.05).After treatment,the MOCA score and BI index score of the study group were higher than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Coenzyme Q10in the adjuvant treatment of Parkinson’s disease can significantly improve the cognitive impairment and emotional disorders in patients,it has good curative effect and less adverse reactions,and can greatly improve the quality of life of patients,which is worthy of clinical promotion.